BWA
GMAB icon

Basecamp Wealth Advisors’s Genmab GMAB Stock Holding History

Basecamp Wealth Advisors’s Portfolio GMAB Stock Details GMAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$33.4K Hold
1,217
– – 0.01% 650
2026
Q1 		$32.7K Hold
1,217
– – 0.01% 661
2025
Q4 		$37.5K Buy
+1,217
New +$37.9K 0.01% 605

Other funds holding GMAB

PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Basecamp Wealth Advisors's GMAB Position: Q2 2026 in Review

Basecamp Wealth Advisors held its Genmab (GMAB) position steady in Q2 2026 at 1,217 shares worth $33.4K. The position accounts for 0.01% of the portfolio, ranked #650.

Basecamp Wealth Advisors first reported a position in GMAB in Q4 2025 and has held it in 3 quarters since. The position peaked at $37.5K in Q4 2025. 289 funds tracked by Wall St. Rank hold GMAB as of Q2 2026.

  • Basecamp Wealth Advisors held 1,217 shares of Genmab worth $33.4K as of Q2 2026.
  • Basecamp Wealth Advisors left its Genmab share count unchanged in Q2 2026.
  • Genmab made up 0.01% of Basecamp Wealth Advisors's portfolio in Q2 2026, its #650 holding.
  • Basecamp Wealth Advisors first reported a position in Genmab in Q4 2025 and has held it in 3 quarters since.
  • Basecamp Wealth Advisors's Genmab position peaked at $37.5K in Q4 2025.
  • 289 funds tracked by Wall St. Rank held Genmab as of Q2 2026.

Based on Basecamp Wealth Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.